REFERENCES
1. Chew NWS, Ng CH, Tan DJH, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 2023;35:414-428.e3.
2. Grunvald E, Shah R, Hernaez R, et al; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163:1198-225.
3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.
4. Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024;47:S52-76.
5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139:e1082-143.
6. McEvoy JW, McCarthy CP, Bruno RM, et al; ESC Scientific Document Group. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018.
7. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52:e364-467.
8. Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al; Peer Review Committee Members. 2022 ACC/AHA guideline for the Diagnosis and Management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2022;146:e334-482.
9. Zeng Y, He H, Zhang L, et al. GWA-based pleiotropic analysis identified potential SNPs and genes related to type 2 diabetes and obesity. J Hum Genet. 2021;66:297-306.
10. Shi LJ, Tang X, He J, Shi W. Genetic evidence for a causal relationship between hyperlipidemia and type 2 diabetes in mice. Int J Mol Sci. 2022;23:6184.
11. King SE, Skinner MK. Epigenetic transgenerational inheritance of obesity susceptibility. Trends Endocrinol Metab. 2020;31:478-94.
12. Pinard A, Jones GT, Milewicz DM. Genetics of thoracic and abdominal aortic diseases. Circ Res. 2019;124:588-606.
14. Stegemann R, Buchner DA. Transgenerational inheritance of metabolic disease. Semin Cell Dev Biol. 2015;43:131-40.
15. Chasman DI, Giulianini F, Demler OV, Udler MS. Pleiotropy-based decomposition of genetic risk scores: association and interaction analysis for type 2 diabetes and CAD. Am J Hum Genet. 2020;106:646-58.
16. Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmental architecture of the features of the insulin-resistance syndrome. Am J Hum Genet. 1997;60:143-52.
17. Shen J, Pan J, Yu G, et al. Genetic interactions and pleiotropy in metabolic diseases: insights from a comprehensive GWAS analysis. J Cell Mol Med. 2024;28:e70045.
18. Bulik-Sullivan BK, Loh PR, Finucane HK, et al; Schizophrenia Working Group of the Psychiatric Genomics Consortium. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47:291-5.
19. Auton A, Brooks LD, Durbin RM, et al; 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68-74.
20. Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between type 2 diabetes and prostate cancer. PLoS Genet. 2020;16:e1009218.
21. Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.
23. Sudmant PH, Rausch T, Gardner EJ, et al; 1000 Genomes Project Consortium. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526:75-81.
24. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826.
25. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50.
26. Berndt SI, Gustafsson S, Mägi R, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013;45:501-12.
27. Kurki MI, Karjalainen J, Palta P, et al; FinnGen. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508-18.
28. Roychowdhury T, Lu H, Hornsby WE, et al; VA Million Veteran Program. Regulatory variants in TCF7L2 are associated with thoracic aortic aneurysm. Am J Hum Genet. 2021;108:1578-89.
29. Tin A, Marten J, Halperin Kuhns VL, et al; German Chronic Kidney Disease Study. A. Million Veteran Program. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet. 2019;51:1459-74.
30. Guindo-Martínez M, Amela R, Bonàs-Guarch S, et al; FinnGen Consortium. The impact of non-additive genetic associations on age-related complex diseases. Nat Commun. 2021;12:2436.
31. Mahajan A, Spracklen CN, Zhang W, et al; FinnGen. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54:560-72.
32. Willer CJ, Schmidt EM, Sengupta S, et al; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274-83.
33. Rohde K, Keller M, la Cour Poulsen L, Blüher M, Kovacs P, Böttcher Y. Genetics and epigenetics in obesity. Metabolism. 2019;92:37-50.
34. Weerakkody R, Ross D, Parry DA, et al; Yale Aortic Institute Data and Repository Team. Targeted genetic analysis in a large cohort of familial and sporadic cases of aneurysm or dissection of the thoracic aorta. Genet Med. 2018;20:1414-22.
35. Song J, Gao N, Chen Z, et al. Shared genetic etiology of vessel diseases: a genome-wide multi-traits association analysis. Thromb Res. 2024;241:109102.
36. Leask MP, Crișan TO, Ji A, Matsuo H, Köttgen A, Merriman TR. The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies. Nat Rev Rheumatol. 2024;20:510-23.
37. Mani A. Update in genetic and epigenetic causes of hypertension. Cell Mol Life Sci. 2024;81:201.
38. Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536:41-7.
39. Scicchitano P, Amati F, Ciccone MM, et al. Hypertriglyceridemia: molecular and genetic landscapes. Int J Mol Sci. 2024;25:6364.
40. Bao Y, Lu P, Wang M, et al. Exploring multimorbidity profiles in middle-aged inpatients: a network-based comparative study of China and the United Kingdom. BMC Med. 2023;21:495.
41. Vora J, Cherney D, Kosiborod MN, et al; CaReMe Global Alliance. Inter-relationships between cardiovascular, renal and metabolic diseases: underlying evidence and implications for integrated interdisciplinary care and management. Diabetes Obes Metab. 2024;26:1567-81.
42. Jia X, Yang Y, Chen Y, et al. Multivariate analysis of genome-wide data to identify potential pleiotropic genes for type 2 diabetes, obesity and coronary artery disease using MetaCCA. Int J Cardiol. 2019;283:144-50.
43. Lopez-Cortes OD, Trujillo-Sánchez F, Sierra-Ruelas E, Martinez-Lopez E, Di Marzo V, Vizmanos B. Association between the FAAH C385A variant (rs324420) and obesity-related traits: a systematic review. Int J Obes (Lond). 2024;48:188-201.
44. Nam Y, Lee DG, Bang S, Kim JH, Kim JH, Shin H. The translational network for metabolic disease - from protein interaction to disease co-occurrence. BMC Bioinformatics. 2019;20:576.
45. Sekar P, Aji AS, Ariyasra U, et al. A novel interaction between a 23-SNP genetic risk score and monounsaturated fatty acid intake on HbA1c levels in southeast Asian women. Nutrients. 2024;16:3022.
46. Matsumura Y, Wei FY, Sakai J. Epitranscriptomics in metabolic disease. Nat Metab. 2023;5:370-84.
47. Kivimäki M, Strandberg T, Pentti J, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10:253-63.
48. Xi Y, Gao W, Zheng K, et al. The roles of genetic and early-life environmental factors in the association between overweight or obesity and hypertension: a population-based twin study. Front Endocrinol. 2021;12:743962.
49. Grassi G. The sympathetic nervous system in hypertension: roadmap update of a long journey. Am J Hypertens. 2021;34:1247-54.
50. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991-1006.
51. Jia G, Sowers JR, Whaley-Connell AT. Obesity in hypertension: the role of the expanding waistline over the years and insights into the future. Hypertension. 2024;81:687-90.
52. Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34:11-20.
53. Yang Y, Xian W, Wu D, et al. The role of obesity, type 2 diabetes, and metabolic factors in gout: a Mendelian randomization study. Front Endocrinol. 2022;13:917056.
54. Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021;78:1197-205.
55. Du L, Zong Y, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212.
56. Lewis GF, Hegele RA. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes Endocrinol. 2022;10:142-8.
57. Sookoian S, Pirola CJ. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol. 2015;21:711-25.
58. Panzeri I, Pospisilik JA. Epigenetic control of variation and stochasticity in metabolic disease. Mol Metab. 2018;14:26-38.
59. Rojas M, Chávez-Castillo M, Pirela D, et al. Metabolic syndrome: is it time to add the central nervous system? Nutrients. 2021;13:2254.
60. Genkinger JM, Kitahara CM, Bernstein L, et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol. 2015;26:2257-66.
61. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-14.
62. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
63. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444-8.
64. Rhodes KS, Weintraub M, Marchlewicz EH, Rubenfire M, Brook RD. Medical nutrition therapy is the essential cornerstone for effective treatment of “refractory” severe hypertriglyceridemia regardless of pharmaceutical treatment: evidence from a lipid management program. J Clin Lipidol. 2015;9:559-67.
